Journal article

Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients

Jillian K Chan, Elena Hernandez Martinez de Lapiscina, Carolyn Taylor, Ai-Lan Nguyen, Salut Alba-Arbalat, Virginia Devonshire, Ana-Luiza Sayao, Robert Carruthers, Fiona Costello, Anthony Traboulsee

Journal of Neuro-Ophthalmology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020

Abstract

BACKGROUND: Patients with multiple sclerosis (MS) experience progressive thinning in optical coherence tomography (OCT) measures of neuroaxonal structure regardless of optic neuritis history. Few prospective studies have investigated the effects of disease-modifying therapies on neuroaxonal degeneration in the retina. Alemtuzumab is a monoclonal antibody shown to be superior to interferon β-1a in treating relapsing-remitting MS (RRMS). The purpose of this study was to assess the effects of alemtuzumab and first-line injectable treatments on OCT measures of neuroaxonal structure including peripapillary retinal nerve fiber layer (RNFL) thickness and combined ganglion cell-inner plexiform (GCIP..

View full abstract

Grants

Awarded by Instituto de Salud Carlos III, Spain


Funding Acknowledgements

Investigator add-on study to a Sanofi Genzyme-supported, investigator-sponsored open-label treatment trial at the University of British Columbia Hospital. The study was supported by the Instituto de Salud Carlos III, Spain (JR16/0006) and Fondo Europeo de Desarrollo Regional (FEDER) to E. Hernandez Martinez de Lapiscina.J. K. Chan received grant support from Biogen and consulted for Roche. E. Hernandez Martinez de Lapiscina received grant support from Merck (Grant for MS Innovation); consulting from Genzyme. Travel and accommodation support from Roche and Genzyme. She is a member of the IMSVISUAL consortium. A. L. Nguyen received research grants from Novartis, Biogen, Merck-Serono, and MS Research Australia; speaker honoraria and consulting fees from EMD Serono and Teva; and conference travel support from Genzyme-Sanofi, Biogen, and Roche. V. Devonshire received honorarium for speaking from the following companies: Sanofi, Biogen, Serono, Roche, and Novartis. A. L Sayao received speaker honoraria from Merck-Serono, consulted for Merck-Serono, Novartis, Biogen, Roche, and Genzyme. R. Carruthers is the site investigator for studies funded by Novartis, MedImmune, and Roche and receives research support from Teva Innovation Canada, Roche Canada, and Vancouver Coastal Health Research Institute. He has done consulting work and has received honoraria from Roche, EMD Serono, Sanofi, Biogen, Novartis, and Teva. A. Traboulsee received research funding from Biogen, Chugai, Novartis, Roche, and Sanofi Genzyme and consultancy honoraria from Biogen, Roche, Sanofi Genzyme, and Teva Neuroscience. The remaining authors report no conflicts of interest.